Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Barr generic tamoxifen

Executive Summary

Barr expects answer from FDA in mid-September regarding its right to manufacture generic tamoxifen. Barr is distributing an "authorized" generic of Nolvadex under license from AstraZeneca, and the generic company claims it is entitled to launch its own version before the brand's pediatric exclusivity expires in February. Barr may exhaust its existing inventory of tamoxifen in early November according to one estimate; it appears unlikely AstraZeneca will extend the supply agreement through the pediatric exclusivity period (1"The Pink Sheet" Aug. 26, In Brief)...

You may also be interested in...

Barr tamoxifen ANDA must wait

FDA says Barr cannot market generic Nolvadex (tamoxifen) before AstraZeneca's pediatric exclusivity expires Feb. 20. Barr's ANDA was tentatively approved before pediatric exclusivity law passed in 1997, and company's "authorized" distribution agreement expired in August (1"The Pink Sheet" Sept. 2, In Brief)..

Nolvadex generic distribution by Barr to end

Barr's distribution of "authorized" Nolvadex generic will not extend through AstraZeneca's pediatric exclusivity, which began Aug. 20. Barr will distribute its remaining inventories, but the end of discussions on an extension raises possibility the brand could be the only product on the market until exclusivity expires in February. Barr and FDA continue to negotiate the company's right to launch its own tamoxifen during pediatric exclusivity in light of tentative approval granted before passage of pediatric exclusivity legislation (1"The Pink Sheet" Aug. 19, p. 12)...

Abbott Launches Five-Minute POC Rapid COVID-19 Test

Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts